Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Active not recruiting 30 enrolled Henan Cancer Hospital Zhengzhou University · collab

NaSingle-groupOpen-labelTreatment

Summary

A prospective trial design was used to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of locally advanced resectable esophageal squamous cell carcinoma.

Timeline

Start: 2025-03-08
Primary completion: 2025-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Envorimab	Unknown	400 mg	Subcutaneous
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous
Background	Carboplatin	Small molecule	2 unknown	Intravenous
Background	Paclitaxel	Small molecule	50 mg/m2	Intravenous

Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications